Viatris, Inc. (VTRS)
| Market Cap | 13.04B |
| Revenue (ttm) | 17.19B |
| Net Income (ttm) | 760.80M |
| Shares Out | 1.23B |
| EPS (ttm) | 0.62 |
| PE Ratio | 17.08 |
| Forward PE | 3.20 |
| Dividend | $0.47 (4.44%) |
| Ex-Dividend Date | Aug 23, 2022 |
| Volume | 5,060,301 |
| Open | 10.75 |
| Previous Close | 10.75 |
| Day's Range | 10.50 - 10.75 |
| 52-Week Range | 9.45 - 15.60 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 14.51 (+37.0%) |
| Earnings Date | Aug 8, 2022 |
About VTRS
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agent... [Read more...]
Financial Performance
In 2021, Viatris's revenue was $17.89 billion, an increase of 49.73% compared to the previous year's $11.95 billion. Losses were -$1.27 billion, 89.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for VTRS stock is "Buy." The 12-month stock price forecast is 14.51, which is an increase of 37.02% from the latest price.
News
Should I sell Viatris shares after Q2 results failed to meet revenue expectations?
Viatris Inc. (NASDAQ: VTRS) reported its second-quarter results on Monday and lowered the revenue outlook for the 2022 fiscal year. Michael Goettler, CEO of Viatris, said that because of strong operatio...
Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates
Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.
Viatris (VTRS) Surpasses Q2 Earnings Estimates
Viatris (VTRS) delivered earnings and revenue surprises of 8.64% and 0.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris Reports Strong Second Quarter 2022 Results
Reports Total Revenues of $4.12 Billion; U.S. GAAP Net Earnings of $314 Million; Adjusted EBITDA of $1.48 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $803 Million; and Free Cash Flow...
Viatris Q2 Preview: Can Shares Snap Their Downtrend?
Even over the last month, when the S&P 500 has rallied for an 8% gain, Viatris shares have continued their downwards trajectory, declining 5.5% in value.
Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 Cheap Dividend Stocks Yielding More Than 4%
These two companies haven't performed well in the market recently, but that could be an opportunity for investors.
3 High-Yielding Dividend Stocks With Payout Ratios Over 100%
Are these dividend payments at risk?
Billionaires Are Piling Into These 2 Dividend-Paying Pharma Stocks
Billionaires are taking advantage of the weakness in Pfizer and Viatris this year.
2 Deeply Discounted Dividend Stocks With High Yields
These stocks pay a dividend yield of more than 4%.
Viatris Inc. to Release Second Quarter 2022 Financial Results on August 8, 2022
PITTSBURGH , July 1, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its second quarter 2022 financial results on Monday, August 8 before the open of the U.S. financial markets. Chief ...
Viatris (VTRS) Up 13.7% Since Last Earnings Report: Can It Continue?
Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?
2 Bruised Dividend Stocks to Buy While They're Cheap
Lower share prices won't stop them from hiking their dividends.
Why Shares of Viatris Climbed 18.8% in May
The company reported improved net income and free cash flow in the last quarter.
3 Great Dividend Stocks to Buy in June
Investors should be able to count on recurring income with these stocks.
3 High-Yielding Dividend Stocks That Are Trading Below Their Book Values
These stocks are incredibly cheap, and aren't as risky as their low multiples suggest they might be.
Viatris to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
PITTSBURGH , May 20, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced the company will participate in the Goldman Sachs 43rd Annual Global Healthcare Co...
Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals
PITTSBURGH , May 16, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today published its 2021 Sustainability Report, outlining the company's 2021 achievements and prog...
2 Stocks That Are Ridiculously Cheap Right Now
They present very different kinds of bargains.
3 Dirt-Cheap Stocks You Can Buy Right Now
These stocks are inexpensive yet have solid underlying businesses.
Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus
Viatris Inc (NASDAQ: VTRS) reported Q1 FY22 sales of $4.18 billion, down 5% Y/Y (-1% on an operational basis), below the consensus of $4.23 billion. Brands performed better than expectations, such as Li...
Viatris' (VTRS) Q1 Earnings Beat, Revenues Miss Estimates
Viatris (VTRS) beats on Q1 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.